The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against ...
By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback